The neutralizing antibody response against West Nile virus in naturally infected horses (Q40217216)

18 September 2017

The neutralizing antibody response against West Nile virus in naturally infected horses (English)

1 reference

18 September 2017

0 references

2

Theodore C Pierson

1 reference

18 September 2017

5

Sheri L Hanna

1 reference

18 September 2017

7

Robert W Doms

1 reference

18 September 2017

Melissa D Sánchez

1

1 reference

18 September 2017

Marciela M Degrace

series ordinal

3

1 reference

18 September 2017

Lisa M Mattei

series ordinal

4

1 reference

18 September 2017

Fabio Del Piero

series ordinal

6

1 reference

18 September 2017

language of work or name

English

0 references

publication date

20 October 2006

1 reference

18 September 2017

13

1 reference

based on heuristic

inferred from page(s)

published in

Virology

1 reference

18 September 2017

359

1 reference

18 September 2017

2

1 reference

18 September 2017

336-348

1 reference

Serologically defined linear epitopes in the envelope protein of dengue 2 (Jamaica strain 1409).

18 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.047

Human immunoglobulin as a treatment for West Nile virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.047

ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.047

Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.047

Use of a recombinant envelope protein subunit antigen for specific serological diagnosis of West Nile virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.047

Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating West Nile virus infection in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.047

Cyclophosphamide-potentiated West Nile viral encephalitis: relative influence of cellular and humoral factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.047

Antibody responses against wild-type yellow fever virus and the 17D vaccine strain: characterization with human monoclonal antibody fragments and neutralization escape variants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.047

Immunologic responses to West Nile virus in vaccinated and clinically affected horses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.047

West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.047

B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.047

A Critical Role for Induced IgM in the Protection against West Nile Virus Infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.047

Antibody prophylaxis and therapy against West Nile virus infection in wild-type and immunodeficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.047

A new mechanism for the neutralization of enveloped viruses by antiviral antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.047

Chimpanzee Fab fragments and a derived humanized immunoglobulin G1 antibody that efficiently cross-neutralize dengue type 1 and type 2 viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.047

Epitope determinants of a chimpanzee Fab antibody that efficiently cross-neutralizes dengue type 1 and type 2 viruses map to inside and in close proximity to fusion loop of the dengue type 2 virus envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.047

Protective and therapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.047

Loss of active neuroinvasiveness in attenuated strains of West Nile virus: pathogenicity in immunocompetent and SCID mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.047

The role for intravenous immunoglobulin in the treatment of West Nile virus encephalitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.047

Possible benefit of intravenous immunoglobulin therapy in a lung transplant recipient with West Nile virus encephalitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.047

N-Linked Glycosylation of West Nile Virus Envelope Proteins Influences Particle Assembly and Infectivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.047

A recombinant particulate antigen of Japanese encephalitis virus produced in stably-transformed cells is an effective noninfectious antigen and subunit immunogen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.047

Dengue type 2 virus subviral extracellular particles produced by a stably transfected mammalian cell line and their evaluation for a subunit vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.047

Mice immunized with a subviral particle containing the Japanese encephalitis virus prM/M and E proteins are protected from lethal JEV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.047

Generation and Characterization of a Mammalian Cell Line Continuously Expressing Japanese Encephalitis Virus Subviral Particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.047

Murray Valley encephalitis virus recombinant subviral particles protect mice from lethal challenge with virulent wild-type virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.047

Structure of dengue virus: implications for flavivirus organization, maturation, and fusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.047

Differential expression of domain III neutralizing epitopes on the envelope proteins of West Nile virus strains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.047

Japanese encephalitis virus-vaccinia recombinants produce particulate forms of the structural membrane proteins and induce high levels of protection against lethal JEV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.047

A ligand-binding pocket in the dengue virus envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.047

Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.047

A live, attenuated recombinant West Nile virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.047

Structure of West Nile Virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.047

West Nile Outbreak in Horses in Southern France, 2000: The Return after 35 Years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.047

Structural basis of West Nile virus neutralization by a therapeutic antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.047

Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.047

Monoclonal antibodies against the flavivirus West Nile

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.047

A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.047

Chimeric West Nile/dengue virus vaccine candidate: preclinical evaluation in mice, geese and monkeys for safety and immunogenicity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.047

West Nile Virus encephalomyelitis in horses: 46 cases (2001)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.047

Neutralizing monoclonal antibodies against Russian strain of the West Nile virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.047

The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.047

Antigenic structure of flavivirus proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.047

Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.047

Outcome of equids with clinical signs of West Nile virus infection and factors associated with death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.047

Characterization of neutralizing antibodies to West Nile virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.047

NATURAL AND EXPERIMENTAL INFECTION OF EGYPTIAN EQUINES WITH WEST NILE VIRUS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.047

Assessment of the efficacy of a single dose of a recombinant vaccine against West Nile virus in response to natural challenge with West Nile virus-infected mosquitoes in horses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.047

West Nile virus encephalomyelitis in eight horses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.047

Efficacy of killed virus vaccine, live attenuated chimeric virus vaccine, and passive immunization for prevention of West Nile virus encephalitis in hamster model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.047

Immunization of mice against West Nile virus with recombinant envelope protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.047

An analysis of the antibody response against West Nile virus E protein purified by SDS-PAGE indicates that this protein does not contain sequential epitopes for efficient induction of neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.047

Recombinant subviral particles from tick-borne encephalitis virus are fusogenic and provide a model system for studying flavivirus envelope glycoprotein functions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.047

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VIROL.2006.08.047

1 reference

18 September 2017

1 reference